Clinical and echocardiographic disease in patients starting end-stage renal disease therapy

Robert N. Foley, Patrick S. Parfrey, John D. Harnett, Gloria M. Kent, Christopher J. Martin, David C. Murray, Paul E. Barre

Research output: Contribution to journalArticlepeer-review

1050 Scopus citations

Abstract

End-stage renal disease (ESRD) patients have a high cardiovascular mortality rate. Precise estimates of the prevalence, risk factors and prognosis of different manifestations of cardiac disease are unavailable. In this study a prospective cohort of 433 ESRD patients was followed from the start of ESRD therapy for a mean of 41 months. Baseline clinical assessment and echocardiography were performed on all patients. The major outcome measure was death while on dialysis therapy. Clinical manifestations of cardiovascular disease were highly prevalent at the start of ESRD therapy: 14% had coronary artery disease, 19% angina pectoris, 31% cardiac failure, 7% dysrhythmia and 8% peripheral vascular disease. On echocardiography 15% had systolic dysfunction, 32% left ventricular dilatation and 74% left ventricular hypertrophy. The overall median survival time was 50 months. Age, diabetes mellitus, cardiac failure, peripheral vascular disease and systolic dysfunction independently predicted death in all time frames. Coronary artery disease was associated with a worse prognosis in patients with cardiac failure at baseline. High left ventricular cavity volume and mass index were independently associated with death after two years. The independent associations of the different echocardiographic abnormalities were: systolic dysfunction-older age and coronary artery disease; left ventricular dilatation-male gender, anemia, hypocalcemia and hyperphosphatemia; left ventricular hypertrophy-older age, female gender, wide arterial pulse pressure, low blood urea and hypoalbuminemia. We conclude that clinical and echocardiographic cardiovascular disease are already present in a very high proportion of patients starting ESRD therapy and are independent mortality factors.

Original languageEnglish (US)
Pages (from-to)186-192
Number of pages7
JournalKidney international
Volume47
Issue number1
DOIs
StatePublished - Jan 1995

Bibliographical note

Funding Information:
This research was funded in its initial phases by the Canadian Heart

Fingerprint Dive into the research topics of 'Clinical and echocardiographic disease in patients starting end-stage renal disease therapy'. Together they form a unique fingerprint.

Cite this